Activation of KATP channels increases anticancer drug delivery to brain tumors and survival

Temozolomide delivery to brain tumors was significantly improved when combined with the potassium channel activator minoxidil sulfate.

• Intravenously administered temozolomide crossed the blood-brain tumor barrier at a relatively low amount.
• Herceptin did not effectively cross the blood-brain tumor barrier when administered intravenously.
• Co-infusion of minoxidil sulfate with temozolomide or Herceptin enhanced selective drug delivery to brain tumors.
• The combination of temozolomide and Herceptin demonstrated a greater anti-tumor effect compared to either drug alone.
• Increased drug delivery may improve survival outcomes in mice with glioblastoma multiforme when using potassium channel agonists.

AI simplified